News, Publications & Insights

Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.

PARI Partner Project News

Partner Project News

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

PARI Publication

PARI Publication

A Novel Human Factors Approach for a New Platform-Based, Breath-Triggered Nebuliser

Published

June 18, 2014

Category

PARI Publications

The eFlow ‘‘closed system’’(CS) - a novel device platform for liquid aerosol drug-device combinations.

The eFlow ‘‘closed system’’(CS) - a novel device platform for liquid aerosol drug-device combinations.

Published

May 12, 2014

Category

Publications

Some cystic fibrosis patients do not tolerate tobramycin dry powder inhalation.

Some cystic fibrosis patients do not tolerate tobramycin dry powder inhalation.

Published

September 11, 2013

Category

Publications

Topical Drug Delivery in Chronic Rhinosinusitis Patients before and after Sinus Surgery Using Pulsating Aerosols.

Topical Drug Delivery in Chronic Rhinosinusitis Patients before and after Sinus Surgery Using Pulsating Aerosols.

Published

June 19, 2013

Categories

PARI Publications
Publications

Pulsating Aerosols - New Therapy Options for Upper Airway Diseases.

Pulsating Aerosols - New Therapy Options for Upper Airway Diseases.

Published

November 13, 2012

Category

Publications

Assessing Modeled CO2 Retention and Rebreathing of a Facemask Designed for Efficient Delivery of Aerosols to Infants.

Assessing Modeled CO2 Retention and Rebreathing of a Facemask Designed for Efficient Delivery of Aerosols to Infants.

Contact us

eFlow-partneringpari.com

Two smiling men in a blue circle. The central man wears glasses and a light blue shirt. The man on the left has a beard and a blue patterned shirt.

PARI Business Development Team